Blood Samples and/or bone marrow assessments for complete remission (CR), complete tumor clearance (CTC), or hematologic response (HR) from bone marrow 56 days [clinicaltrials_resource:c0a55426590f149e92903c265d7a92bd]
Response rate of patients with refactory, relapsed, or poor risk acute myeloid leukemia (AML) expressing Fms-like tyrosine kinase 3 (FLT-3) activating mutations. CR is defined as presence of less than 5% myeloblasts in bone marrow with normalized peripheral blood cell counts. HR is defined as a 50% or more decrease in the absolute number of peripheral blast count or at least a 50% reduction in bone marrow blasts.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Blood Samples and/or bone marrow assessments for complete remission (CR), complete tumor clearance (CTC), or hematologic response (HR) from bone marrow 56 days [clinicaltrials_resource:c0a55426590f149e92903c265d7a92bd]
Response rate of patients with refactory, relapsed, or poor risk acute myeloid leukemia (AML) expressing Fms-like tyrosine kinase 3 (FLT-3) activating mutations. CR is defined as presence of less than 5% myeloblasts in bone marrow with normalized peripheral blood cell counts. HR is defined as a 50% or more decrease in the absolute number of peripheral blast count or at least a 50% reduction in bone marrow blasts.
Bio2RDF identifier
c0a55426590f149e92903c265d7a92bd
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c0a55426590f149e92903c265d7a92bd
measure [clinicaltrials_vocabulary:measure]
Blood Samples and/or bone marr ...... response (HR) from bone marrow
time frame [clinicaltrials_vocabulary:time-frame]
description
Response rate of patients with ...... duction in bone marrow blasts.
identifier
clinicaltrials_resource:c0a55426590f149e92903c265d7a92bd
title
Blood Samples and/or bone marr ...... (HR) from bone marrow 56 days
@en
type
label
Blood Samples and/or bone marr ...... 55426590f149e92903c265d7a92bd]
@en